# Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

> **NCT03805841** · PHASE2 · TERMINATED · sponsor: **Rain Oncology Inc** · enrollment: 41 (actual)

## Conditions studied

- NSCLC, Stage IV
- NSCLC Stage IIIB
- NSCLC, Stage IIIC
- NSCLC, Recurrent
- EGFR Exon 20 Insertion Mutation
- HER2-activating Mutation
- ERBB Fusion
- NRG1 Fusion

## Interventions

- **DRUG:** tarloxotinib bromide

## Key facts

- **NCT ID:** NCT03805841
- **Lead sponsor:** Rain Oncology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-13
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-04-23
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** enrollment pause
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805841, "Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03805841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*